{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:23:01Z","timestamp":1793312581718,"version":"4.5.0"},"reference-count":62,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T00:00:00Z","timestamp":1730160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Transl Neurol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antisense oligonucleotides, which are used to silence target genes, are gaining attention as a novel drug discovery modality for proteinopathies. However, while clinical trials for neurodegenerative diseases like amyotrophic lateral sclerosis have been conducted in recent years, the results have not always been favorable. The results from a Phase III trial of the antisense oligonucleotide, that is, tofersen, which targets <jats:italic>SOD1<\/jats:italic> mRNA, showed decreased levels of cerebrospinal fluid SOD1 and plasma neurofilament light chain but no improvements in primary clinical endpoint. Moreover, case reports pertaining to patients with amyotrophic lateral sclerosis carrying <jats:italic>FUS<\/jats:italic> and <jats:italic>C9orf72<\/jats:italic> mutations who received antisense oligonucleotide\u2010based treatments have demonstrated a notable reduction in the targeted protein (thus providing the proof of mechanism) but with no discernible clinical benefits. There are several possible reasons why antisense oligonucleotides knockdown fails to achieve proof of concept, which need to be addressed: on\u2010target adverse effects resulting from the loss of function of target gene and irreversible neuronal death cascade due to toxic protein accumulation, among other factors. This review provides an overview of the current status and discusses the prospects of antisense oligonucleotides treatment for amyotrophic lateral sclerosis.<\/jats:p>","DOI":"10.1002\/acn3.52234","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T09:59:51Z","timestamp":1730282391000},"page":"3054-3063","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Rethinking antisense oligonucleotide therapeutics for amyotrophic lateral sclerosis"],"prefix":"10.1002","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4740-1675","authenticated-orcid":false,"given":"Daisuke","family":"Ito","sequence":"first","affiliation":[{"name":"Memory Center Keio University School of Medicine  Tokyo Japan"},{"name":"Department of Neurology Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Neurology Keio University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,29]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22157"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1134108"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.10.093"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah5436"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4893"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716153"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716793"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26259"},{"key":"e_1_2_14_10_1","unstructured":"SciencesWL.Wave Life Sciences Provides Update on Phase 1b\/2a PRECISION\u2010HD Trials.2021. Accessed April 27 2024.https:\/\/ir.wavelifesciences.com\/news\u2010releases\/news\u2010release\u2010details\/wave\u2010life\u2010sciences\u2010provides\u2010update\u2010phase\u20101b2a\u2010precision\u2010hd"},{"key":"e_1_2_14_11_1","unstructured":"CirianoD.Update on Tominersen Clinical Trials.2022. Accessed April 27 2024.https:\/\/medically.roche.com\/content\/dam\/pdmahub\/restricted\/neurology\/factor\u2010h\u20102022\/FACTOR\u2010H\u20102022\u2010presentation\u2010ciriano\u2010update\u2010on\u2010tominersen\u2010clinical\u2010trials.pdf"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006846"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073902"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-015-1460-x"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204705"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102495"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2011.09.020"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2023.2189925"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab416"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1905039"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01615-z"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1625"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2005056"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/72842"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10465"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182343365"},{"key":"e_1_2_14_27_1","unstructured":"BiogenI.Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis.2022. Accessed April 27 2024.https:\/\/investors.biogen.com\/news\u2010releases\/news\u2010release\u2010details\/biogen\u2010and\u2010ionis\u2010announce\u2010topline\u2010phase\u20101\u2010study\u2010results"},{"key":"e_1_2_14_28_1","unstructured":"WaveL.Sciences.2023. Accessed April 27 2024.https:\/\/ir.wavelifesciences.com\/node\/10706\/pdf"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01557-6"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1064"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2021.05.020"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-019-0685-7"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-018-0293-z"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI139741"},{"key":"e_1_2_14_35_1","doi-asserted-by":"crossref","unstructured":"BrownAL WilkinsOG KeussMJ et\u00a0al.Common ALS\/FTD Risk Variants in UNC13A Exacerbate its Cryptic Splicing and Loss Upon TDP\u201043 Mislocalization.BioRxiv2021.","DOI":"10.21203\/rs.3.rs-386600\/v1"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09320"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22038"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddn035"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.10.186"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111001"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/22768"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXG.0000000000000105"},{"key":"e_1_2_14_43_1","unstructured":"Quralis.2023. Accessed April 27 2024.https:\/\/www.quralis.com\/news\/quralis\u2010reveals\u2010newest\u2010program\u2010targeting\u2010unc13a\u2010rna\u2010mis\u2010splicing\u2010incorporating\u2010its\u2010flexaso\u2010platform\/"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu138"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddx397"},{"key":"e_1_2_14_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61075-2"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20226"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120187"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4085"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.11.037"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191284198"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210951"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0710373105"},{"key":"e_1_2_14_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12164"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa332"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms5335"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0914128107"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1231012100"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz139"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-00984-y"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02788-5"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02937-4"}],"container-title":["Annals of Clinical and Translational Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acn3.52234","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T16:12:48Z","timestamp":1734451968000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.52234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,29]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1002\/acn3.52234"],"URL":"https:\/\/doi.org\/10.1002\/acn3.52234","archive":["Portico"],"relation":{},"ISSN":["2328-9503","2328-9503"],"issn-type":[{"value":"2328-9503","type":"print"},{"value":"2328-9503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,29]]},"assertion":[{"value":"2024-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}